Kaken 1H FY18 (YE Mar'19) Results - First Glance
Key highlights NHI pricing pressure continues to take its toll on Kakenâs flagship drug, Artz (down 16% to „12.4b, ~30% of FY17 sales), driving...
497 Views
Negative Impact of Price Cuts to Continue; New Opportunities Offer Marginal Benefit
We reiterate our âEqual-weightâ rating on the stock after reviewing our model post 1Q FY18 (YE Mar-19) earningsLong Listed product sales under NHI...
539 Views
Kaken Pharmaceutical Co (4521:Tokyo): A Top-Class Pharmaceutical Company at a Discount to Fair Value
Share could have potential 77% upside. Using enterprise DCF method, our fair value estimate for the common stock is Yen 11,073. Shares of Kaken...
471 Views